Nasdaq · CIK 0001119774
CGEN COMPUGEN LTD
Insider trading from SEC Form 4. Last filing Jul 30, 2026. Close $2.13 on Oct 9, 2026, +45% from the 52-week low and -31% from the high.
In brief
COMPUGEN LTD (CGEN) has 23 SEC Form 4 filings on file from 12 insiders, the latest filed on Jul 30, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
11 open-market trades have been scored at CGEN. The newest: Zurit Levine (SVP, Business Development) sold $4,688 of stock on Jul 9, 2026, filed Jul 13, 2026, scored 0 (weak), under a 10b5-1 plan. The largest of the 11 shown: Zurit Levine (SVP, Business Development) sold $24k on Mar 26, 2026, scored 0 (weak), under a 10b5-1 plan. 2 insiders sold within 14 days of each other around Apr 24, 2026.
7 Form 144 notices of planned sales are on file, the latest filed Apr 27, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at COMPUGEN LTD, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Zurit Levine SVP, Business Development sell | $4,688 1,875 shares | -6% | +86% from low-20% from high | |
| 8Weak | Eran Ophir President and CEO sell | $16k 5,000 shares | -31% | +148% from low0% from high | |
| 0Weak | Zurit Levine SVP, Business Development sell | $6,400 2,000 shares | -6% | +148% from low0% from high | |
| 0Weak | Zurit Levine SVP, Business Development sell | $5,600 2,000 shares | -6% | +130% from low0% from high | |
| 8Weak | Eran Ophir President and CEO sell | $15k 5,000 shares | -31% | +130% from low0% from high | |
| 0Weak | Zurit Levine SVP, Business Development sell | $8,013 3,125 shares | -10% | +113% from low0% from high | |
| 0Weak | Zurit Levine SVP, Business Development sell | $8,013 3,125 shares | -10% | +113% from low0% from high | |
| 0Weak | Zurit Levine SVP, Business Development sell | $19k 7,875 shares | -25% | +97% from low-2% from high | |
| 8Weak | Eran Ophir President and CEO sell | $12k 5,625 shares | -33% | +86% from low-7% from high | |
| 0Weak | Zurit Levine SVP, Business Development sell | $7,700 3,500 shares | -11% | +86% from low-7% from high | |
| 0Weak | Zurit Levine SVP, Business Development sell | $24k 11,875 shares | -29% | +75% from low-13% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Apr 27, 2026 | Levine Zurit Officer | 4,000 0.00% of outstanding | $12k | Apr 24, 2026 | $64k |
| Apr 27, 2026 | Ophir Eran Officer | 5,000 0.01% of outstanding | $15k | Apr 24, 2026 | $27k |
| Apr 15, 2026 | Levine Zurit Officer | 2,000 0.00% of outstanding | $5,520 | Apr 14, 2026 | $59k |
| Apr 15, 2026 | Ophir Eran Officer | 5,000 0.01% of outstanding | $14k | Apr 14, 2026 | $12k |
| Apr 13, 2026 | Levine Zurit Officer | 2,000 0.00% of outstanding | $4,960 | Apr 10, 2026 | $53k |
| Apr 2, 2026 | Ophir Eran Officer | 5,625 0.01% of outstanding | $12k | Apr 1, 2026 | none |
| Mar 26, 2026 | Levine Zurit Officer | 24,375 0.03% of outstanding | $50k | Mar 26, 2026 | none |
Transactions
The newest 50 of 65 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026 | Anat Cohen-Dayag director | AGrant or award Share Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jul 30, 2026 |
| Jul 29, 2026 | Savitzky Kinneret Livnat director | AGrant or award Ordinary Shares | +7,500 | $0.00 | $0 | 20,850 | Jul 30, 2026 |
| Jul 29, 2026 | David Silberman Chief Financial Officer | AGrant or award Ordinary Shares | +19,500 | $0.00 | $0 | 55,000 | Jul 30, 2026 |
| Jul 29, 2026 | Eran Ophir President and CEO | AGrant or award Share Option (right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Jul 30, 2026 |
| Jul 29, 2026 | Michelle Mahler Chief Medical Officer | AGrant or award Ordinary Shares | +13,500 | $0.00 | $0 | 36,625 | Jul 30, 2026 |
| Jul 29, 2026 | Zurit Levine SVP, Business Development | AGrant or award Ordinary Shares | +18,000 | $0.00 | $0 | 47,375 | Jul 30, 2026 |
| Jul 29, 2026 | Mathias Hukkelhoven director | AGrant or award Ordinary Shares | +7,500 | $0.00 | $0 | 17,500 | Jul 30, 2026 |
| Jul 29, 2026 | Eran Perry director | AGrant or award Ordinary Shares | +7,500 | $0.00 | $0 | 17,500 | Jul 30, 2026 |
| Jul 29, 2026 | Sanford S Zweifach director | AGrant or award Ordinary Shares | +7,500 | $0.00 | $0 | 20,180 | Jul 30, 2026 |
| Jul 29, 2026 | Russo Sharon Kredo SVP, Research & Discovery | AGrant or award Ordinary Shares | +18,000 | $0.00 | $0 | 37,500 | Jul 30, 2026 |
| Jul 29, 2026 | Pierre Ferre Chief Operating Officer | AGrant or award Share Option (right to buy)derivative | +70,000 | $0.00 | $0 | 70,000 | Jul 30, 2026 |
| Jul 29, 2026 | Gilead Halevy director | AGrant or award Ordinary Shares | +7,500 | $0.00 | $0 | 18,907 | Jul 30, 2026 |
| Jul 29, 2026 | Mathias Hukkelhoven director | AGrant or award Share Option (right to buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jul 30, 2026 |
| Jul 29, 2026 | Michelle Mahler Chief Medical Officer | AGrant or award Share Option (right to buy)derivative | +18,000 | $0.00 | $0 | 18,000 | Jul 30, 2026 |
| Jul 29, 2026 | David Silberman Chief Financial Officer | AGrant or award Share Option (right to buy)derivative | +26,000 | $0.00 | $0 | 26,000 | Jul 30, 2026 |
| Jul 29, 2026 | Savitzky Kinneret Livnat director | AGrant or award Share Option (right to buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jul 30, 2026 |
| Jul 29, 2026 | Sanford S Zweifach director | AGrant or award Share Option (right to buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jul 30, 2026 |
| Jul 29, 2026 | Zurit Levine SVP, Business Development | AGrant or award Share Option (right to buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jul 30, 2026 |
| Jul 29, 2026 | Russo Sharon Kredo SVP, Research & Discovery | AGrant or award Share Option (right to buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jul 30, 2026 |
| Jul 29, 2026 | Gilead Halevy director | AGrant or award Share Option (right to buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jul 30, 2026 |
| Jul 29, 2026 | Eran Perry director | AGrant or award Share Option (right to buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jul 30, 2026 |
| Jul 9, 2026 | Zurit Levine SVP, Business Development | MOption exercise Ordinary Shares10b5-1 | +1,875 | $0.83 | $1,555 | 31,250 | Jul 13, 2026 |
| Jul 9, 2026 | Zurit Levine SVP, Business Development | SOpen-market sale Ordinary Shares10b5-1 | -1,875 | $2.50 | $4,688 | 29,375 | Jul 13, 2026 |
| Jul 9, 2026 | Zurit Levine SVP, Business Development | MOption exercise Share Option (right to buy)derivative10b5-1 | -1,875 | $0.00 | $0 | 3,750 | Jul 13, 2026 |
| Apr 24, 2026 | Eran Ophir President and CEO | MOption exercise Ordinary Shares10b5-1 | +5,000 | $0.83 | $4,146 | 16,375 | Apr 27, 2026 |
| Apr 24, 2026 | Zurit Levine SVP, Business Development | MOption exercise Ordinary Shares10b5-1 | +2,000 | $1.15 | $2,300 | 31,375 | Apr 27, 2026 |
| Apr 24, 2026 | Eran Ophir President and CEO | SOpen-market sale Ordinary Shares10b5-1 | -5,000 | $3.20 | $16k | 11,375 | Apr 27, 2026 |
| Apr 24, 2026 | Zurit Levine SVP, Business Development | SOpen-market sale Ordinary Shares10b5-1 | -2,000 | $3.20 | $6,400 | 29,375 | Apr 27, 2026 |
| Apr 24, 2026 | Eran Ophir President and CEO | MOption exercise Share Option (right to buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 14,375 | Apr 27, 2026 |
| Apr 24, 2026 | Zurit Levine SVP, Business Development | MOption exercise Share Option (right to buy)derivative10b5-1 | -2,000 | $0.00 | $0 | 52,000 | Apr 27, 2026 |
| Apr 14, 2026 | Eran Ophir President and CEO | MOption exercise Ordinary Shares10b5-1 | +5,000 | $0.83 | $4,146 | 16,375 | Apr 15, 2026 |
| Apr 10, 2026 | Zurit Levine SVP, Business Development | MOption exercise Ordinary Shares10b5-1 | +1,125 | $0.83 | $933 | 30,500 | Apr 15, 2026 |
| Apr 14, 2026 | Zurit Levine SVP, Business Development | MOption exercise Ordinary Shares10b5-1 | +2,000 | $1.15 | $2,300 | 31,375 | Apr 15, 2026 |
| Apr 14, 2026 | Zurit Levine SVP, Business Development | SOpen-market sale Ordinary Shares10b5-1 | -2,000 | $2.80 | $5,600 | 29,375 | Apr 15, 2026 |
| Apr 14, 2026 | Eran Ophir President and CEO | SOpen-market sale Ordinary Shares10b5-1 | -5,000 | $2.90 | $15k | 11,375 | Apr 15, 2026 |
| Apr 10, 2026 | Zurit Levine SVP, Business Development | MOption exercise Ordinary Shares10b5-1 | +2,000 | $1.15 | $2,300 | 32,500 | Apr 15, 2026 |
| Apr 14, 2026 | Zurit Levine SVP, Business Development | MOption exercise Share Option (right to buy)derivative10b5-1 | -2,000 | $0.00 | $0 | 54,000 | Apr 15, 2026 |
| Apr 14, 2026 | Eran Ophir President and CEO | MOption exercise Share Option (right to buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 19,375 | Apr 15, 2026 |
| Apr 10, 2026 | Zurit Levine SVP, Business Development | SOpen-market sale Ordinary Shares10b5-1 | -3,125 | $2.56 | $8,013 | 29,375 | Apr 15, 2026 |
| Apr 10, 2026 | Zurit Levine SVP, Business Development | MOption exercise Share Option (right to buy)derivative10b5-1 | -1,125 | $0.00 | $0 | 5,625 | Apr 15, 2026 |
| Apr 10, 2026 | Zurit Levine SVP, Business Development | MOption exercise Share Option (right to buy)derivative10b5-1 | -2,000 | $0.00 | $0 | 56,000 | Apr 15, 2026 |
| Apr 10, 2026 | Zurit Levine SVP, Business Development | MOption exercise Ordinary Shares10b5-1 | +1,125 | $0.83 | $933 | 30,500 | Apr 13, 2026 |
| Apr 10, 2026 | Zurit Levine SVP, Business Development | MOption exercise Ordinary Shares10b5-1 | +2,000 | $1.15 | $2,300 | 32,500 | Apr 13, 2026 |
| Apr 10, 2026 | Zurit Levine SVP, Business Development | SOpen-market sale Ordinary Shares10b5-1 | -3,125 | $2.56 | $8,013 | 29,375 | Apr 13, 2026 |
| Apr 10, 2026 | Zurit Levine SVP, Business Development | MOption exercise Share Option (right to buy)derivative10b5-1 | -1,125 | $0.00 | $0 | 5,625 | Apr 13, 2026 |
| Apr 10, 2026 | Zurit Levine SVP, Business Development | MOption exercise Share Option (right to buy)derivative10b5-1 | -2,000 | $0.00 | $0 | 56,000 | Apr 13, 2026 |
| Apr 7, 2026 | Zurit Levine SVP, Business Development | MOption exercise Ordinary Shares10b5-1 | +2,500 | $0.83 | $2,073 | 31,875 | Apr 9, 2026 |
| Apr 7, 2026 | Zurit Levine SVP, Business Development | SOpen-market sale Ordinary Shares10b5-1 | -2,500 | $2.30 | $5,750 | 29,375 | Apr 9, 2026 |
| Apr 8, 2026 | Zurit Levine SVP, Business Development | MOption exercise Ordinary Shares10b5-1 | +4,375 | $0.83 | $3,628 | 33,750 | Apr 9, 2026 |
| Apr 8, 2026 | Zurit Levine SVP, Business Development | MOption exercise Ordinary Shares10b5-1 | +1,000 | $1.15 | $1,150 | 34,750 | Apr 9, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Anat Cohen-Dayagdirector
- Pierre FerreChief Operating Officer
- Gilead Halevydirector
- Mathias Hukkelhovendirector
- Russo Sharon KredoSVP, Research & Discovery
- Zurit LevineSVP, Business Development
- Savitzky Kinneret Livnatdirector
- Michelle MahlerChief Medical Officer
- Eran OphirPresident and CEO
- Eran Perrydirector
- David SilbermanChief Financial Officer
- Sanford S Zweifachdirector
Questions about CGEN
Answered from the filings on this page, as of the latest one.
Are insiders buying CGEN?
No. In the last 90 days no insider at COMPUGEN LTD bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade CGEN on the open market?
Zurit Levine (SVP, Business Development) sold $4,688 of CGEN on Jul 9, 2026 and filed the Form 4 on Jul 13, 2026. InsiderTell scored 0 (weak), under a 10b5-1 plan.
How many insiders file Form 4 at COMPUGEN LTD?
12 people have filed a Form 4 at COMPUGEN LTD, among them Anat Cohen-Dayag (director), Pierre Ferre (Chief Operating Officer), Gilead Halevy (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.